{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:07Z","timestamp":1791397387483,"version":"4.3.3"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,2]]},"abstract":"Summary<\/jats:title>\n \n Peripheral T\u2010cell lymphomas (\n PTCL<\/jats:styled-content>\n ) have suboptimal outcomes using conventional\n CHOP<\/jats:styled-content>\n (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti\u2010folate pralatrexate, the first drug approved for patients with relapsed\/refractory\n PTCL<\/jats:styled-content>\n , provided a rationale to incorporate it into the front\u2010line setting. This phase 2 study evaluated a novel front\u2010line combination whereby cyclophosphamide, etoposide, vincristine and prednisone (\n CEOP<\/jats:styled-content>\n ) alternated with pralatrexate (\n CEOP<\/jats:styled-content>\n \u2010P) in\n PTCL<\/jats:styled-content>\n . Patients achieving a complete or partial remission (\n CR<\/jats:styled-content>\n \/\n PR<\/jats:styled-content>\n ) were eligible for consolidative stem cell transplantation (\n SCT<\/jats:styled-content>\n ) after 4 cycles. Thirty\u2010three stage\n II<\/jats:styled-content>\n \u2010\n IV PTCL<\/jats:styled-content>\n patients were treated: 21\n PTCL<\/jats:styled-content>\n \u2010not otherwise specified (64%), 8 angioimmunoblastic T cell lymphoma (24%) and 4 anaplastic large cell lymphoma (12%). The majority (61%) had stage\n IV<\/jats:styled-content>\n disease and 46% were International Prognostic Index high\/intermediate or high risk. Grade 3\u20134 toxicities included anaemia (27%), thrombocytopenia (12%), febrile neutropenia (18%), mucositis (18%), sepsis (15%), increased creatinine (12%) and liver transaminases (12%). Seventeen patients (52%) achieved a\n CR<\/jats:styled-content>\n . The 2\u2010year progression\u2010free survival and overall survial, were 39% (95% confidence interval 21\u201357) and 60% (95% confidence interval 39\u201376), respectively. Fifteen patients (45%) (12\n CR<\/jats:styled-content>\n ) received\n SCT<\/jats:styled-content>\n and all remained in\n CR<\/jats:styled-content>\n at a median follow\u2010up of 21\u00b75\u00a0months.\n CEOP<\/jats:styled-content>\n \u2010P did not improve outcomes compared to historical data using\n CHOP<\/jats:styled-content>\n . Defining optimal front line therapy in\n PTCL<\/jats:styled-content>\n continues to be a challenge and an unmet need.\n <\/jats:p>","DOI":"10.1111\/bjh.13855","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T02:45:25Z","timestamp":1449024325000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["A phase\n II<\/scp>\n study of cyclophosphamide, etoposide, vincristine and prednisone (\n CEOP<\/scp>\n ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T\u2010cell lymphoma (\n PTCL<\/scp>\n ): final results from the T\u2010 cell consortium trial"],"prefix":"10.1111","volume":"172","author":[{"given":"Ranjana H.","family":"Advani","sequence":"first","affiliation":[{"name":"Medical Oncology Stanford Cancer Institute Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Lechowicz","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University School of Medicine Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Beaven","sequence":"additional","affiliation":[{"name":"Medicine\u2010Oncology Duke University Medical Center Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Loberiza","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Carson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Washington University School of Medicine St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Tufts Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"Yale University Cancer Center New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Medical Oncology Jefferson University Hospital Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Pinter\u2010Brown","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology UCLA Geffen School of Medicine Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Advanced Medicine University of Chicago Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology British Columbia Cancer Agency Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"M. Vose","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu443"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.623256"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1880-4"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.06.011"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_8_11_1","first-page":"504","article-title":"Final Analysis of the RO\u2010CHOP Phase Ib\/II Study: romidepsin in Association with CHOP in Patients with Peripheral T\u2010Cell Lymphoma (PTCL)","volume":"124","author":"Dupuis J.","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2456"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.742521"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.816700"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227579"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.003"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3119"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733"},{"key":"e_1_2_8_23_1","first-page":"408","article-title":"R\u2010CHOP with Etoposide Substituted for Doxorubicin (R\u2010CEOP): excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines","volume":"114","author":"Moccia A.A.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2153"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm514"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5611"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood.V124.21.4434.4434","article-title":"Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T\u2010Cell Lymphoma (PTCL)","volume":"124","author":"Pinter\u2010Brown L.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2872"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.267"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"e_1_2_8_38_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13855","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:59:28Z","timestamp":1696244368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/bjh.13855"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13855","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725980628.793539740","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,2]]},"assertion":[{"value":"2015-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}